ClinicalTrials.gg
Status unknownNCT04481607Updated Jan 10, 2022

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

A Phase 1 interventional study of TQB3454 in Advanced Solid Tumor or Hematologic Tumor, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-10.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.

02

Conditions studied

  • Advanced Solid Tumor or Hematologic Tumor
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. (ECOG) performance status score of 0 to 1; ≥12 weeks.
  1. Advanced solid tumors or hematological . 3. Adequate laboratory indicators. 4. No pregnant or breastfeeding women, and a negative pregnancy test. 5. Understood and Signed an form.

Exclusion criteria

Exclusion Criteria:

    1. Has central nervous system or system leukemia. 2.Previous anti-tumor treatment:

      1. Has received IDH1 mutation inhibitor.
      2. Has received systemic anti-tumor therapy or radiotherapy within 14 days before the first dose.
      3. Has received oral targeted drugs, less than 5 drug half-lives from first dose.
      4. The related toxicity of previous anti-tumor therapy has not recovered to ≤ grade 2, except for hair loss.

        3.Complicated disease and medical history:

      <!-- -->

      1. Active or .
      2. Abnormal kidney.
      3. Abnormal cardiovascular and cerebrovascular.
      4. Abnormal gastrointestinal.
      5. Has medical history of immunodeficiency.
      6. Has bleeding (hemoptysis), coagulopathy, or been using warfarin, aspirin, and other antiplatelet agglutination drugs.
      7. Has uncontrollable systemic bacterial, fungal or viral active infections.
      8. Has medical history of idiopathic pulmonary fibrosis,or tissue pneumonia.
      9. Has allergic constitution or previous severe allergy; or known allergy to ingredients of study drug.
      10. Has neurological or mental disorders.
      11. Has a history of drug abuse or drug addict.
      12. Has received major surgery, open , or obvious traumatic injury within 4 weeks before the first dose.
      13. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.

        1. Has participated in other clinical trials within 30 days before participating in this trial.
        1. Female patients during pregnancy or lactation. 6. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
        1. criteria for solid tumors:

      <!-- -->

      1. Has any signs of bleeding constitution.
      2. Has any CTCAE ≥ grade 3 bleeding or bleeding event,within 4 weeks before the first dose.
      3. Has unhealed wounds, fractures, active ulcers of the stomach and duodenum, ulcerative colitis and other digestive tract diseases.
      4. Imaging (CT or MRI) shows that the tumor has invaded the circumference of important blood vessels.
      5. Has uncontrollable pleural effusion, pericardial effusion or ascites that still need repeated drainage.

criteria for blood tumor:

a) Has severe life-threatening leukemia complications.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    TQB3454 tablets

    TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.

    Drug: TQB3454

Interventions

  • TQB3454 tablets is a small molecule oral drug.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT.

    Time frame: Baseline up to 28 days

Secondary outcomes

  1. Cmax

    Cmax is the maximum plasma concentration of TQB3454 or metabolite(s).

    Time frame: Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;

  2. Tmax

    To characterize the pharmacokinetics of TQB3454 by assessment of time to reach maximum plasma concentration.

    Time frame: Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;

  3. AUC0-t

    To characterize the pharmacokinetics of TQB3454 by assessment of area under the plasma concentration time curve from zero to infinity.

    Time frame: Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;

  4. Objective response rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: up to 60 weeks

  5. Progression-free survival (PFS)

    PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.

    Time frame: Up to 60 weeks

  6. 2-hydroxyglutaric acid

    Correlation between 2-hydroxyglutaric acid and efficacy

    Time frame: Hour 0(pre-dose) on single dose; Hour 0(pre-dose) of day1, day8, day15, day28 on multiple dose of first cycle; hour 0(pre-dose) of day15, day28 of second and third cycle; hour 0(pre-dose) of day28 of fourth to eighth cycle.Each cycle is 28 days.

07

Study locations

5 of 5 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing 100089, China
    Recruiting
    • Lin Shen, Doctor · Contactdoctorshenlin@sina.cn · 010-88196340
    • Lin Shen, Doctor · Principal investigator
  • The Affiliated Hosptial of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
    Recruiting
  • Tianjing Medical University Cancer Institute&Hospital
    Tianjin, Tianjin 300020, China
    Recruiting
  • Hematology Hospital of Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300041, China
    Recruiting
  • The First Affiliated Hosptial Zhejiang University School of Medical
    Hangzhou, Zhejiang 311100, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Dec 2022, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2020
First posted
Jul 22, 2020
StartActual
Aug 24, 2020
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2022
Last update
Jan 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04481607
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Aug 24, 2020
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Jan 10, 2022

Study contacts

Lin Shen, Doctor
Contact
doctorshenlin@sina.cn
010-88196340

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IDH1 Inhibitor TQB3454

Start the discussion